Beckabir, Wolfgang
Zhou, Mi http://orcid.org/0000-0001-8144-3468
Lee, Jin Seok
Vensko, Steven P.
Woodcock, Mark G. http://orcid.org/0000-0001-7348-4980
Wang, Hsing-Hui
Wobker, Sara E.
Atassi, Gatphan http://orcid.org/0000-0003-3694-2123
Wilkinson, Alec D.
Fowler, Kenneth
Flick, Leah M.
Damrauer, Jeffrey S. http://orcid.org/0000-0001-8148-0285
Harrison, Michael R.
McKinnon, Karen P.
Rose, Tracy L.
Milowsky, Matthew I. http://orcid.org/0000-0002-8965-8129
Serody, Jonathan S. http://orcid.org/0000-0003-4568-1092
Kim, William Y. http://orcid.org/0000-0001-7922-2156
Vincent, Benjamin G. http://orcid.org/0000-0002-1762-2282
Funding for this research was provided by:
Merck & Co., Inc. | Merck Sharp and Dohme
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1F30CA278317-01A1)
Article History
Received: 18 July 2023
Accepted: 2 May 2024
First Online: 24 May 2024
Competing interests
: The authors declare the following competing interests: Pfizer (Stock and Other Ownership Interests); Loxo/Lilly (Consulting or Advisory Role); Merck, Roche/Genentech, Bristol-Myers Squibb, Mirati Therapeutics, Incyte, Seagen, G1 Therapeutics, Alliance Foundation Trials, Alliance for Clinical Trials in Oncology, Clovis Oncology, Arvinas, ALX Oncology, Loxo, Hoosier Cancer Network (Research Funding); Elsevier, Medscape, Research to Practice (Other Relationship).